Compare CTS & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTS | NBTX |
|---|---|---|
| Founded | 1896 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | N/A | 2020 |
| Metric | CTS | NBTX |
|---|---|---|
| Price | $44.74 | $22.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 184.4K | 49.5K |
| Earning Date | 10-28-2025 | 09-30-2025 |
| Dividend Yield | ★ 0.36% | N/A |
| EPS Growth | ★ 3.07 | N/A |
| EPS | ★ 1.98 | N/A |
| Revenue | ★ $531,522,000.00 | $11,930,711.00 |
| Revenue This Year | $5.73 | N/A |
| Revenue Next Year | $4.00 | $136.64 |
| P/E Ratio | $22.55 | ★ N/A |
| Revenue Growth | ★ 3.61 | N/A |
| 52 Week Low | $34.02 | $2.82 |
| 52 Week High | $57.49 | $30.35 |
| Indicator | CTS | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 59.56 | 57.62 |
| Support Level | $42.68 | $20.83 |
| Resistance Level | $45.65 | $22.05 |
| Average True Range (ATR) | 1.39 | 0.91 |
| MACD | 0.12 | 0.06 |
| Stochastic Oscillator | 79.09 | 78.81 |
CTS Corp operates in the electronics industry. The company is a manufacturer of Sensors, Electronic components, and Actuators. It designs, manufactures, and sells a broad line of sensors, electronic components, and actuators mainly to original equipment manufacturers (OEM) for the aerospace and defense, industrial, information technology, medical, telecommunications, and transportation markets. Geographically, it derives a majority of its revenue from the United States and also has a presence in China; Singapore; the Czech Republic; Taiwan, Denmark, and other countries.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.